1st Quarter - Report

EMERGENT BIOSOLUTIONS INC. for EMERGENT BIOSOLUTIONS INC

Firm
Client
Income
—
Expenses
$1,620,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Disaster Planning/Emergencies DIS

FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government Re-authorization of the Pandemic and All-Hazards Preparedness Act NDAA - provisions related to biological and chemical defense Department of Defense appropriations for Medical Countermeasures FDA regulatory issues Issues related to Priority Review Voucher programs Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines

LobbyistCovered position, as disclosed
GRANT BARBOSA —
CHRIS FRECH —
KATHERINE GETTY New —
JILL HAMAKER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government Re-authorization of the Pandemic and All-Hazards Preparedness Act NDAA - provisions related to biological and chemical defense Department of Defense appropriations for Medical Countermeasures FDA regulatory issues Issues related to Priority Review Voucher programs Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines

LobbyistCovered position, as disclosed
GRANT BARBOSA —
CHRIS FRECH —
KATHERINE GETTY —
JILL HAMAKER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Homeland Security HOM

FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government Re-authorization of the Pandemic and All-Hazards Preparedness Act NDAA - provisions related to biological and chemical defense Department of Defense appropriations for Medical Countermeasures FDA regulatory issues Issues related to Priority Review Voucher programs Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines

LobbyistCovered position, as disclosed
GRANT BARBOSA —
CHRIS FRECH —
KATHERINE GETTY —
JILL HAMAKER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.